Company news
Aldeyra Therapeutics, Inc. news in 2020
Aldeyra Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
December 21, 2020
Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis
December 16, 2020
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
December 7, 2020
Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update
November 4, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update
October 28, 2020
Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients
September 8, 2020
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
August 5, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update
July 29, 2020
Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners
July 13, 2020
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease
July 6, 2020
Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program
June 14, 2020
Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease
June 3, 2020
Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting
May 19, 2020
Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs
May 6, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update
April 29, 2020
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629
April 13, 2020
Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection
March 23, 2020
Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones
March 11, 2020
Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease
March 11, 2020
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Fourth-Quarter and Full-Year 2019 Financial Results and Corporate Update
March 4, 2020
Aldeyra Therapeutics to Host 2020 Research & Development Day
February 10, 2020
Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board
January 27, 2020
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
January 20, 2020
Aldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors
January 13, 2020
Calls in 2020
Decks in 2020
- Corporate Update (May 2020)
Corporate update · 16 slides · May 20, 2020
- Technical Presentation (March 2020)
Technical · 7 slides · Mar 24, 2020
- Investor Day (February 2020)
Investor day · 86 slides · Feb 24, 2020